Autosomal Dominant Intermediate Charcot-Marie-Tooth Disease Type C

Autosomal dominant intermediate Charcot-Marie-Tooth disease type C (often shortened to AD-CMTD type C or CMTDIC) is a rare inherited nerve disease. It mainly affects the long nerves to the feet and hands. People slowly develop weakness, wasting of muscles, numbness, burning or pins-and-needles, foot deformities and balance problems. “Intermediate” means that nerve conduction speed is between the typical values seen in demyelinating CMT and axonal CMT.NCBI+2Monarch Initiative+2

Autosomal dominant intermediate Charcot-Marie-Tooth disease type C (often written as CMTDIC or DI-CMT type C) is a very rare inherited nerve disease. It mainly affects the long nerves to the feet, legs, hands and arms. These nerves slowly stop working properly, so the person develops weakness, muscle wasting and loss of feeling in the hands and feet over many years. Doctors call it “intermediate” because the nerve conduction speed on tests is between that seen in demyelinating CMT and axonal CMT (usually about 25–60 meters per second in the median nerve). MalaCards+1

This condition is autosomal dominant, so one changed copy of the gene is enough to cause disease, and each child has a 50% chance to inherit it. Many cases of CMTDIC are linked to disease-causing changes (mutations) in the YARS1 gene, which encodes tyrosyl-tRNA synthetase, a protein needed for normal nerve cell function.cmtausa.org+1 As of now, there is no cure and no drug approved specifically for CMTDIC. Management focuses on rehabilitation, orthoses, surgery and symptom-control medicines.PMC+1

CMTDIC is inherited in an autosomal dominant way. This means a person usually needs only one changed copy of the gene from either parent to develop the disease. Most reported families have a change (mutation) in the YARS1 gene on chromosome 1p35, which makes an enzyme called tyrosyl-tRNA synthetase that is important for normal protein building inside nerve cells. MalaCards+1

People with CMTDIC usually have slowly progressive symptoms that often start in childhood, teenage years or adult life. The disease typically begins in the lower legs and feet and can later involve the hands. Because it is so rare (prevalence estimated at less than 1 in 1,000,000 people worldwide), most information comes from a small number of families studied over many years. MalaCards+1

---

Other names

Doctors and researchers use several names for autosomal dominant intermediate Charcot-Marie-Tooth disease type C. Knowing these names helps when reading medical papers or genetic reports, because they all refer to the same condition. MalaCards+1

“Charcot-Marie-Tooth disease, dominant intermediate C (CMTDIC)” is the most common formal medical name. It states that this is a type of Charcot-Marie-Tooth disease, that it is dominantly inherited, and that it belongs to the intermediate conduction-speed group, specifically subtype C. MalaCards+1

“Autosomal dominant intermediate Charcot-Marie-Tooth disease type C” adds the word “autosomal” to show that the gene is on a non-sex chromosome (chromosome 1) and that only one mutated copy is needed. The “type C” label separates it from other dominant intermediate subtypes such as types A, B, D, E, F and G. MalaCards+1

“Charcot-Marie-Tooth neuropathy, dominant intermediate C” and similar phrases like “Charcot-Marie-Tooth disease dominant intermediate type C” or “Cmtdic” are shorthand names used in research databases and genetic reports. They describe the same disease but in slightly different wording depending on the database (for example OMIM, Orphanet, Disease Ontology or NIH rare disease lists). MalaCards+1

Another group of aliases includes “Charcot-Marie-Tooth disease caused by mutation in YARS” or “YARS Charcot-Marie-Tooth disease.” These names highlight the main known disease-causing gene and are often used in genetic testing panels and molecular reports rather than in everyday clinical practice. MalaCards

---

Types

Within autosomal dominant intermediate CMT, doctors do not usually divide patients into rigid official subtypes beyond the “type C” label. However, based on age of onset and severity, several clinical patterns are often recognised. These patterns help describe the disease course but are not separate genetic diseases. MalaCards+1

1. Childhood-onset classic form
In this pattern, symptoms start in later childhood or early teenage years. The child may have trouble running, frequent falls and high-arched feet. Weakness and wasting in the lower legs appear slowly, and nerve conduction studies already show intermediate slowing at a young age. MalaCards+1

2. Adolescent-onset form
Here, the first signs appear around the teenage years. The person may notice difficulty in sports, ankle sprains, or problems keeping up with friends. Over time, the same pattern of distal weakness, sensory loss and reduced reflexes as in the classic form becomes clear, but onset is slightly later. MalaCards+1

3. Adult-onset slowly progressive form
Some people first develop symptoms in adult life, even as late as their 30s to 50s. They may notice gradual foot drop, tripping and numbness. Progression is often slow over decades. Nerve conduction velocities still fall into the intermediate range, and family history may reveal other affected relatives. MalaCards+1

4. Mild late-onset form
A few individuals have very mild signs, such as slightly weak ankle muscles or absent ankle reflexes, and may be diagnosed only after a family member is found to have CMTDIC. They still carry the disease-causing YARS1 mutation, but symptoms remain minimal or appear only in later adult life. This reflects variable expressivity, which is common in monogenic neuropathies. MalaCards+1

---

Causes

For autosomal dominant intermediate CMT type C, the main cause is a change in a single gene. Other “causes” listed here are factors or mechanisms that explain how the gene change leads to disease, or why the disease can look different from person to person.

1. Pathogenic variants in YARS1
The primary cause is a heterozygous (one-copy) pathogenic mutation in the YARS1 gene on chromosome 1p35. This gene encodes tyrosyl-tRNA synthetase 1, which is essential for attaching the amino acid tyrosine to its transfer RNA during protein synthesis in cells, including long peripheral neurons. MalaCards+1

2. Autosomal dominant inheritance pattern
Because CMTDIC is autosomal dominant, a person usually inherits the mutation from an affected mother or father. Each child of an affected parent has a 50% chance of receiving the mutated gene, which explains why the disease can appear across several generations in a family. MalaCards+1

3. De novo (new) mutation in YARS1
In some rare cases, the YARS1 mutation may arise for the first time in a child, without being present in either parent. This is called a de novo mutation. The child then becomes the first affected person in the family and can pass the mutation to future children. Cell+1

4. Altered tyrosyl-tRNA synthetase function
Mutations in YARS1 change the structure or activity of tyrosyl-tRNA synthetase. This abnormal enzyme may attach tyrosine incorrectly, work too slowly, or gain toxic functions. All these changes can disturb protein synthesis and signalling in long motor and sensory neurons. MalaCards+1

5. Length-dependent axonal stress
Peripheral nerves to the feet and hands are very long. When protein handling is disturbed by the YARS1 defect, these long axons are under special stress and are more likely to degenerate over time. This explains why symptoms start distally in feet and hands. MalaCards+1

6. Mixed demyelinating and axonal pathology
Nerve biopsy studies in CMTDIC show loss of large myelinated fibres, segmental remyelination and age-dependent axonal degeneration, but no onion-bulb formations. This “mixed” pathology fits the intermediate nerve conduction speeds and contributes to progressive weakness and sensory loss. MalaCards+1

7. Disrupted axonal transport
Long axons need efficient transport of proteins, organelles and signalling molecules. Abnormal tRNA synthetase activity can interfere with these processes, so the distal parts of the axon do not receive the materials they need. Over years, this promotes axonal thinning and degeneration. Neupsy Key+1

8. Cellular stress responses in neurons
Misfolded or abnormal YARS1 protein may trigger stress pathways inside nerve cells, such as endoplasmic reticulum stress or unfolded-protein responses. These stress signals can make neurons more vulnerable to injury and may speed up nerve fibre loss. WJGNet+1

9. Genetic modifiers in other CMT-related genes
Malacards and other genetic databases list additional genes connected to CMTDIC, including other aminoacyl-tRNA synthetases and neuropathy genes. Variants in these modifier genes might not cause disease on their own but can change how severe the YARS1-related neuropathy becomes in an individual. MalaCards+1

10. Variable penetrance of the mutation
Not everyone with the same YARS1 mutation is affected to the same degree. Some people have clear signs, while others have very mild or almost no symptoms. This variable penetrance is common in autosomal dominant neuropathies and reflects the interaction of the mutation with other genes and the environment. MalaCards+1

11. Ageing of peripheral nerves
Natural ageing already causes some loss of nerve fibres and slowing of nerve conduction. In people with CMTDIC, the YARS1 defect makes nerves more fragile, so age-related changes add on top of the inherited disease and can worsen weakness and numbness over time. Wikipedia+1

12. Repeated mechanical stress and micro-trauma
Long-standing foot deformities and weak ankle muscles can cause abnormal gait and repeated minor injuries in nerves and muscles. While this is not a primary cause, it may worsen the symptoms and structural changes created by the underlying genetic defect. Wikipedia+1

13. Co-existing metabolic diseases (for example diabetes)
If a person with CMTDIC develops another condition that also damages nerves, such as diabetes or severe vitamin deficiency, the total nerve injury can be greater. These added metabolic stresses act as secondary contributors on top of the main YARS1 mutation. Neupsy Key+1

14. Exposure to neurotoxic drugs
Some chemotherapy agents and certain other medicines are known to cause peripheral neuropathy. In someone with CMTDIC, such drugs can aggravate nerve damage and lead to faster loss of strength and sensation, although they do not cause the original disease. Neupsy Key+1

15. Nutritional deficiencies
Deficiencies of vitamins important for nerve health (especially B12, B1 and folate) can independently cause neuropathy. When these deficiencies occur in a person with CMTDIC, symptoms may appear earlier or be more severe than if the genetic disease were present alone. Neupsy Key+1

16. Hormonal and endocrine disturbances
Some endocrine illnesses can worsen neuropathy or muscle weakness. Although they are not direct causes of CMTDIC, their presence may modify the course of the disease and can influence how disabled a person becomes. Neupsy Key+1

17. Lifestyle factors such as inactivity
Low physical activity leads to deconditioning and muscle loss even in healthy people. In CMTDIC, where nerve input is already reduced, inactivity can contribute to faster muscle wasting and poorer balance, making the inherited neuropathy more obvious. Orthobullets+1

18. Excessive physical overload without support
On the other hand, heavy unassisted physical work or intense high-impact sports can strain weak muscles and joints. Without proper physiotherapy or bracing, this overload can cause tendon and joint damage, worsening gait and function in someone with the underlying disease. Orthobullets+1

19. Small-population or founder effects
In some rare families or communities, the same YARS1 mutation may have been passed down from a distant ancestor. When people in that group marry within the same community, the mutation can appear more often. This founder effect increases the local frequency of the disease. MalaCards+1

20. Still-unknown genetic and environmental factors
Research continues to find additional genes and pathways linked to intermediate forms of CMT. It is likely that other subtle genetic variants and environmental exposures modify how CMTDIC appears, even though the central cause remains the YARS1 mutation. MalaCards+1

---

Symptoms

1. Distal muscle weakness in the feet and lower legs
The most typical symptom is weakness in the muscles that lift and move the feet and ankles. People may notice that their feet slap when walking, or they have trouble standing on their heels or toes. This weakness reflects chronic damage to motor nerves in the peroneal distribution. MalaCards+1

2. Distal muscle wasting (atrophy)
Over time, the muscles in the lower legs become thinner and wasted, often giving the legs an “inverted champagne bottle” appearance. This happens because the nerves that normally activate those muscles slowly lose their function and the muscle fibres shrink. MalaCards+1

3. Foot deformities (often high-arched feet / pes cavus)
Many people develop structural changes in the feet, such as high arches, clawed toes or hammertoes. These deformities result from long-standing imbalance between weak and relatively strong muscles and from altered weight bearing across the foot. MalaCards+1

4. Difficulty walking and frequent tripping or falls
Weak ankle muscles and altered foot shape cause instability when walking. People may trip easily, especially on uneven ground, and may have a “steppage gait,” lifting the knees higher than normal to avoid dragging the toes. MalaCards+1

5. Weakness in the hands and distal arms
As the disease progresses, weakness may also appear in the hands. Tasks such as buttoning clothes, writing, opening jars or using small tools become difficult. This reflects involvement of distal arm nerves after the legs have been affected for some time. MalaCards+1

6. Numbness and reduced sensation in feet and hands
People often notice numbness, tingling or “pins and needles” in the toes and soles of the feet, and later in the fingers. Examination shows reduced ability to feel light touch, vibration or pain in these areas, caused by damage to sensory nerve fibres. MalaCards+1

7. Reduced or absent deep tendon reflexes
Reflexes at the ankles and sometimes at the knees become weak or absent in CMTDIC. This is because the reflex arc depends on healthy sensory and motor fibres. When these fibres are damaged, the quick muscle response to a tendon tap disappears. MalaCards+1

8. Atrophy of extensor digitorum brevis muscle
A specific finding described in this disease is wasting of a small foot muscle called the extensor digitorum brevis, located on the top of the foot. This can be seen as a hollow area where a small bulge would normally appear, and it reflects chronic nerve damage in the peroneal territory. MalaCards

9. Balance problems and unsteady gait
Loss of position and vibration sense in the feet, together with weakness, makes it harder to keep balance, especially in the dark or with eyes closed. People may sway when standing or feel unsteady when turning quickly, increasing the risk of falls. neurosci.cn+1

10. Foot pain or discomfort
Some individuals experience aching, burning or sharp pains in the feet and lower legs. The pain can come from nerve injury itself, from muscle fatigue or from pressure in deformed joints and shoes. Pain severity varies widely between people with the same diagnosis. Wikipedia+1

11. Hand clumsiness and poor fine motor skills
When hand nerves are affected, fine finger movements become slow or clumsy. Tasks like typing, sewing or playing musical instruments can be more difficult. This symptom often appears later than foot problems and can affect day-to-day independence. MalaCards+1

12. Fatigue with walking or standing
Because muscles are weaker and less efficient, people with CMTDIC often feel tired after walking, standing or climbing stairs for a short time. This is not just general tiredness but reflects the extra effort needed to move weakened limbs and keep balance. neurosci.cn+1

13. Decreased vibration and position sense
On neurological examination, doctors often find that vibration sense (tested with a tuning fork) and position sense (awareness of joint movement) are reduced in the big toes and ankles. This sensory loss is an objective sign of large-fiber neuropathy. MalaCards+1

14. Progressive but usually slowly worsening course
CMTDIC usually progresses slowly over many years. People may notice that tasks they could do in youth become harder in middle age. However, the rate of change is generally gradual, and many individuals remain able to walk for decades, sometimes with braces or aids. MalaCards+1

15. Psychosocial impact and reduced quality of life
Living with a chronic neuropathy can affect mood, self-confidence and social life. Foot deformities, use of braces or walking aids, and fear of falls can limit activities. Managing these emotional and social effects is an important part of holistic care, even though they are not direct nerve symptoms. Wiley Online Library+1

---

Diagnostic tests

Diagnosis of autosomal dominant intermediate CMT type C is based on clinical features, family history, electrodiagnostic studies and genetic testing. Other tests help to rule out different causes of neuropathy or to understand the structural changes in nerves and muscles.

1. General neurological examination 
The neurologist carefully checks muscle strength, tone, reflexes and sensation in all four limbs. In CMTDIC, they usually find distal weakness and wasting, reduced or absent ankle reflexes, and sensory loss in a “glove and stocking” pattern. This basic examination guides all further testing. MalaCards+1

2. Inspection of feet and legs 
The doctor looks for high arches, clawed toes, hammertoes, calluses and changes in leg shape. Visible thinning of the lower legs and atrophy of the extensor digitorum brevis muscle are common in CMTDIC. These visual signs support the diagnosis of a chronic hereditary neuropathy. MalaCards+1

3. Deep tendon reflex testing 
Reflex hammers are used to tap the Achilles and patellar tendons. In CMTDIC, ankle reflexes are often absent and knee reflexes may be reduced. This objective finding supports damage to the peripheral reflex arc and helps distinguish peripheral neuropathy from brain or spinal cord disease. MalaCards+1

4. Sensory examination with simple tools 
The doctor tests light touch, pin-prick, vibration (with a tuning fork) and joint position sense at toes and fingers. Reduced or absent responses in the distal parts of the limbs confirm sensory nerve involvement, which is a key feature of hereditary motor and sensory neuropathies like CMTDIC. MalaCards+1

5. Gait analysis and observation of walking 
Watching the person walk in the clinic gives important information. A high-stepping gait, ankle instability or frequent tripping suggests distal weakness. Turning, walking on uneven surfaces or walking in a straight line heel-to-toe can reveal subtle balance issues typical of CMT diseases. Orthobullets+1

6. Heel and toe walking tests 
The person is asked to walk on their heels and then on their toes. Failure to walk on heels points to weakness of foot-lifting muscles, while difficulty walking on toes suggests calf weakness. These simple bedside tests help quantify distal leg weakness in CMTDIC. Orthobullets+1

7. Romberg balance test 
In the Romberg test, the patient stands with feet together and then closes their eyes. Swaying or loss of balance when the eyes are closed but not when they are open suggests impaired position sense in the feet. This sign supports damage to large sensory fibres in hereditary neuropathies. neurosci.cn+1

8. Manual muscle testing of distal and proximal muscles
The examiner grades muscle strength (for example from 0 to 5) by asking the patient to move against resistance. In CMTDIC, distal muscles in the feet and hands are weaker than proximal muscles in the hips and shoulders. Recording these scores helps follow disease progression over time. Orthobullets+1

9. Routine blood tests to rule out other neuropathies
Blood tests such as fasting glucose, vitamin B12, thyroid function, kidney and liver tests do not diagnose CMTDIC directly, but they help exclude acquired causes of neuropathy (for example diabetes, severe vitamin deficiency or kidney failure). This ensures that the identified neuropathy truly reflects the inherited disease. Neupsy Key+1

10. Serum creatine kinase (CK) measurement 
Creatine kinase is an enzyme released when muscles break down. In CMTDIC, CK is often normal or only mildly raised, which supports a neuropathic rather than primary muscle disease. Measuring CK is useful when weakness is present, to help separate nerve and muscle disorders. Neupsy Key+1

11. Targeted genetic testing for YARS1 variants 
Molecular genetic testing is the key confirmatory test. Many laboratories offer panels for CMT genes. Finding a heterozygous pathogenic or likely pathogenic variant in YARS1 that matches the clinical picture confirms the diagnosis of autosomal dominant intermediate CMT type C. MalaCards+1

12. Nerve biopsy (usually sural nerve) 
In selected cases, a small sensory nerve (often the sural nerve near the ankle) is biopsied. In CMTDIC, microscopy shows reduced numbers of large myelinated fibres, segmental demyelination and remyelination, and axonal degeneration but typically no onion-bulb formations. Biopsy is now used less often because genetic testing is widely available. MalaCards+1

13. Motor nerve conduction studies 
Motor nerve conduction studies measure how fast and how strongly electrical signals travel along motor nerves. In CMTDIC, median motor nerve conduction velocities usually fall in the intermediate range (about 25–45 or up to 60 m/s), which lies between typical demyelinating CMT1 and axonal CMT2 values. MalaCards+2neurosci.cn+2

14. Sensory nerve conduction studies 
Sensory nerve conduction tests evaluate the response of sensory fibres. In CMTDIC, sensory responses may be reduced in size or absent in distal limbs, while conduction speeds show similar intermediate slowing. These findings, combined with motor studies, strongly support an intermediate hereditary neuropathy. neurosci.cn+1

15. Electromyography (needle EMG) 
Needle EMG studies look at the electrical activity of muscles at rest and during contraction. In CMTDIC, EMG often shows signs of chronic denervation and reinnervation, such as large motor unit potentials, especially in distal muscles. EMG helps confirm that weakness is due to nerve, not muscle, disease. WJGNet+1

16. F-wave and late response studies
F-waves are long-loop responses that travel up and down motor nerves. In intermediate CMT, these responses may be delayed, reflecting involvement of proximal segments of the nerve. Adding F-wave analysis refines the electrodiagnostic picture and supports the classification as an intermediate neuropathy. neurosci.cn+1

17. X-ray imaging of feet and ankles 
Simple X-ray images can show high arches, hammertoes and other bony deformities caused by long-standing muscle imbalance. Although X-rays do not show nerve damage, they help orthopaedic surgeons and physiatrists plan braces, insoles or corrective surgery when needed. Orthobullets+1

18. MRI of lower limb muscles 
Magnetic resonance imaging (MRI) can reveal patterns of muscle wasting and fatty replacement in the legs. In CMT, including intermediate types, MRI often shows characteristic distal muscle involvement. These patterns can support the diagnosis and are sometimes used in research to track disease progression. Muscular Dystrophy Association+1

19. Peripheral nerve ultrasound 
High-resolution ultrasound allows doctors to measure nerve size and structure at different points in the limbs. In CMTDIC, nerve enlargement may be mild or moderate compared with demyelinating forms, fitting its “intermediate” character. Ultrasound is a helpful non-invasive tool in specialised centres. neurosci.cn+1

20. MRI of the spine or brain when needed 
If symptoms or signs are unusual, MRI of the spine or brain may be done to exclude other neurological conditions, such as spinal cord disease or multiple sclerosis. These scans are usually normal in CMTDIC, and a normal result supports a peripheral rather than central cause of weakness and sensory loss. Wikipedia+1

---

Non-Pharmacological Treatments

1. Physiotherapy (physical therapy)
Physiotherapy is one of the most important non-drug treatments for CMTDIC. A physiotherapist designs gentle stretching, strengthening and endurance exercises to keep muscles working as well as possible and to delay contractures (stiff, short muscles).physio-pedia.com+2nhs.uk+2 The purpose is to maintain movement, strength, balance and walking ability. The main mechanism is simple: regular, low-impact movement keeps joints flexible, muscles stronger and blood flow better, which slows secondary damage from inactivity.

2. Balance and gait training
Many people with CMTDIC have poor balance, unsteady gait and frequent falls. Special balance and gait exercises, often done on different surfaces or with visual and cueing tasks, help the brain and remaining nerves learn safer ways to move.MDPI+1 The purpose is to reduce falls and improve walking confidence. The mechanism is neuroplasticity: repeated practice teaches the nervous system to use visual, inner-ear and remaining sensory information more efficiently.

3. Strength training for weak muscles
Supervised, low-to-moderate resistance training can strengthen partly weakened muscles without over-fatiguing them.MDPI+1 The purpose is to support joints, improve function and reduce fatigue. The mechanism is the usual muscle response to training: controlled overload stimulates muscle fibers and motor units that are still alive, which can increase force and endurance when done carefully.

4. Stretching and contracture prevention
Daily stretching of ankles, calves, toes, wrists and fingers helps keep joints mobile and reduces the risk of permanent stiffness and deformity.nhs.uk+1 The purpose is to preserve range of motion and delay painful contractures. The mechanism is that sustained, gentle lengthening of muscles and tendons prevents them from shortening and keeps surrounding tissues more flexible.

5. Ankle-foot orthoses (AFOs)
Many people develop foot drop and ankle instability. Ankle-foot orthoses are light braces that hold the ankle in a better position for walking.physio-pedia.com+2Pod NMD+2 Their purpose is to prevent tripping, improve step clearance and reduce fatigue. They work mechanically by supporting weak muscles and guiding the ankle into a more stable, energy-efficient posture during each step.

6. Custom shoes and foot orthoses (insoles)
Custom shoes, arch supports and insoles are used to manage high-arched (pes cavus) or flat feet, corns and pressure points.Pod NMD+1 The purpose is to reduce pain, redistribute pressure and stabilize the foot. The mechanism is purely mechanical: extra support changes how weight is spread across the foot and limits abnormal twisting of joints with each step.

7. Night splints for feet and ankles
Night splints keep the ankle and toes in a stretched, neutral position while sleeping.Pod NMD+1 The purpose is to stop muscles and tendons from shortening overnight, which is a common problem in people with pes cavus deformity. The mechanism is prolonged low-force stretch, which tells the tissue to maintain length and reduces morning stiffness.

8. Occupational therapy (OT)
Occupational therapists focus on daily activities like dressing, writing, cooking and computer use. They can teach joint-protection techniques, energy conservation and use of adaptive devices (special cutlery, pens, keyboards, etc.).cmtausa.org+1 The purpose is to keep people independent at home, school and work. The mechanism is practical: changing tools, layouts and habits reduces strain on weak muscles and saves energy.

9. Hand therapy and fine motor training
Some people have weakness of the small hand muscles. Hand therapy uses exercises, splints and adaptive tools to preserve grip, pinch strength and coordination.cmtausa.org The purpose is to maintain hand function for daily tasks. The mechanism is keeping remaining motor units active and training the brain to use them in more efficient patterns.

10. Hydrotherapy and swimming
Exercising in water reduces stress on weak ankles and knees while still allowing strengthening and balance work.MDPI+1 The purpose is to build fitness with lower fall risk and less joint pain. The mechanism is that water supports body weight and the gentle resistance of water challenges muscles in a safe, graded way.

11. Pain psychology and cognitive-behavioural therapy (CBT)
Chronic nerve pain and disability can lead to fear, low mood and poor sleep. Pain psychology and CBT teach coping skills, relaxation and pacing.PMC+1 The purpose is to reduce the suffering and impact of pain, even if pain level does not fully disappear. The mechanism is changing thoughts, emotions and behaviours that amplify pain signals in the brain.

12. Fatigue and energy-management education
People often feel tired because walking and daily tasks demand more effort. Teaching pacing, rest breaks, task planning and use of aids helps.PMC+1 The purpose is to do more with less exhaustion. The mechanism is simply spreading effort across the day, avoiding sudden over-use that worsens weakness and pain.

13. Home safety and fall-prevention modifications
Simple changes like removing loose rugs, using grab bars, better lighting and using supportive railings can lower fall risk.nhs.uk+1 The purpose is to prevent fractures, head injury and fear of movement. The mechanism is reducing environmental hazards so that weak ankles and poor sensation cause fewer accidents.

14. Podiatry and skin-care for feet
Because sensation is poor, people may not notice blisters, pressure sores or infections. Regular podiatry visits, nail care and daily self-checks are important.nhs.uk+1 The purpose is to prevent ulcers, infections and deformity-related complications. The mechanism is early detection and treatment of minor foot problems before they become serious.

15. Respiratory and speech therapy (when needed)
In advanced or complex cases, breathing muscles or speech can be affected. Respiratory therapy may teach breathing exercises, cough assistance and airway clearance, while speech therapy helps with articulation and swallowing strategies.PMC+1 The purpose is to maintain safe breathing and communication. Mechanism: targeted training of affected muscles and use of compensatory techniques.

16. Genetic counselling for patient and family
Because CMTDIC is autosomal dominant, genetic counselling explains inheritance, testing options and reproductive choices, including prenatal or preimplantation testing.Orpha+1 The purpose is to support informed family planning and emotional coping. The mechanism is clear education, risk calculation and support for personal decisions.

17. Vocational rehabilitation
As weakness progresses, some jobs become unsafe or impossible. Vocational rehab helps with workplace adaptations, new career planning and legal support for disability accommodations.PMC+1 The purpose is to maintain employment and income as long as possible. Mechanism: changing work tasks, hours and environment to fit physical limits.

18. Community support groups and peer networks
CMT-specific organizations and online communities let patients share experiences, tips and emotional support.PMC+1 The purpose is to reduce isolation and improve coping. The mechanism is social connection: seeing others manage the same condition increases hope and practical knowledge.

19. Assistive devices (canes, walkers, wheelchairs)
Mobility aids are tools, not signs of failure. A cane, crutches, walker or wheelchair can greatly increase safety and independence when walking is hard.nhs.uk+1 The purpose is to prevent falls and allow longer distances. Mechanism: extra support and an alternative way to move when leg muscles are too weak.

20. Long-term multidisciplinary follow-up
Optimal care usually needs a team: neurologist, physiotherapist, occupational therapist, orthopaedic surgeon, podiatrist, psychologist and genetic counsellor.PMC+1 The purpose is to monitor progression, adjust therapy and address new problems early. Mechanism: regular check-ups catch changes in strength, gait, feet, breathing and mental health so that interventions are updated in time.

---

Drug Treatments

Right now no medicine is FDA-approved to cure or specifically treat autosomal dominant intermediate CMT type C. Drugs are used off-label mainly to treat neuropathic pain, muscle cramps, mood problems and sleep issues, guided by a specialist neurologist or pain doctor.PMC+1 Labels from accessdata.fda.gov provide evidence for these drugs in other neuropathic pain conditions (such as diabetic neuropathy or post-herpetic neuralgia), but not specifically in CMTDIC.FDA Access Data+2FDA Access Data+2

Below, “dosage” is general label-level information and not personal advice. A doctor must adjust dose, timing and combinations for each person’s age, weight, kidneys, liver and other medicines.

1. Gabapentin (Neurontin and related brands)
Gabapentin is an anti-seizure drug widely used for neuropathic pain. FDA labels show benefit for conditions like post-herpetic neuralgia.FDA Access Data+2FDA Access Data+2 Typical adult dosing starts low (for example 300 mg/day) and is slowly increased in divided doses, often up to 1800–3600 mg/day if tolerated. The purpose is to reduce burning, shooting pain and allodynia. It works by binding to calcium channels in nerve cells and reducing release of excitatory neurotransmitters. Common side effects are sleepiness, dizziness and weight gain.

2. Pregabalin (Lyrica)
Pregabalin is a related drug approved for several types of neuropathic pain.FDA Access Data+2FDA Access Data+2 Usual adult dosing for neuropathic pain begins around 150 mg/day, split into two or three doses, and may be increased (for example to 300 mg/day or more) as tolerated. The purpose is to calm overactive pain nerves and improve sleep. Mechanism is similar to gabapentin, with strong binding to α2δ subunits of calcium channels. Side effects can include dizziness, swelling, weight gain and blurred vision.

3. Duloxetine (Cymbalta)
Duloxetine is a serotonin–norepinephrine reuptake inhibitor (SNRI) antidepressant approved for diabetic neuropathic pain and fibromyalgia, along with depression and anxiety.FDA Access Data+2FDA Access Data+2 Typical dosing for neuropathic pain is around 60 mg once daily, sometimes starting at 30 mg. The purpose is to reduce nerve pain and improve mood and sleep. Mechanism: it increases serotonin and norepinephrine in pain pathways in the brain and spinal cord. Side effects may include nausea, dry mouth, sweating and increased blood pressure.

4. Amitriptyline
Amitriptyline is a tricyclic antidepressant long used in low doses for neuropathic pain and poor sleep. FDA labels cover depression; pain use is off-label.FDA Access Data+1 Doctors often start at 10–25 mg at night and slowly increase if needed. The purpose is to help night-time pain and improve sleep quality. Mechanism is serotonin and norepinephrine reuptake inhibition plus direct effects on pain pathways. Common side effects are dry mouth, constipation, drowsiness and weight gain; heart rhythm problems are possible at higher doses.

5. Nortriptyline
Nortriptyline, another tricyclic, is similar to amitriptyline but often a bit better tolerated in terms of drowsiness and weight gain. FDA labels focus on depression, but low-dose use for neuropathic pain is common clinical practice.FDA Access Data Doses may start around 10–25 mg at night and increase stepwise. Purpose and mechanism are similar: modulating pain pathways and improving sleep through monoamine reuptake blockade. Side effects include dry mouth, constipation, dizziness and possible heart conduction changes.

6. Venlafaxine (SNRI)
Venlafaxine is another SNRI antidepressant sometimes used for neuropathic pain when duloxetine is not suitable. FDA labels cover depression, anxiety and some pain conditions, not specifically CMT.FDA Access Data Doses are usually titrated from low (for example 37.5–75 mg/day). Purpose is to treat mood symptoms and provide some pain relief by increasing serotonin and norepinephrine. Side effects include nausea, sweating, possible blood pressure rise and withdrawal symptoms if stopped suddenly.

7. Tramadol (Ultram and similar brands)
Tramadol is a weak opioid with additional serotonin and norepinephrine reuptake effects, used for moderate pain.FDA Access Data+2FDA Access Data+2 Dosing varies; for adults, label doses often start at 50 mg and may be repeated, with strict maximum daily limits. The purpose is to control severe or breakthrough pain when other options fail. Mechanism is mixed opioid agonism and monoamine reuptake inhibition. Side effects include nausea, dizziness, constipation and dangerous risks such as dependence, overdose, serotonin syndrome and seizures, so it must be used with great caution.

8. NSAIDs (e.g., naproxen, ibuprofen)
Non-steroidal anti-inflammatory drugs are not specific for nerve pain but can help muscle, joint and postoperative pain related to deformities or surgery. FDA labels describe dosing and gastrointestinal, kidney and cardiovascular risks.FDA Access Data Purpose is to reduce inflammatory aches, especially after activity or surgery. Mechanism is inhibition of COX enzymes and prostaglandin production. Side effects include stomach irritation, ulcers, kidney strain and increased blood pressure.

9. Baclofen
Baclofen is a muscle relaxant used for spasticity and sometimes for muscle cramps. FDA labels describe oral and liquid forms for spasticity, not specifically CMT.FDA Access Data+2FDA Access Data+2 Dosing starts low and is slowly increased several times daily. The purpose is to lessen painful spasms and stiffness. Mechanism: it activates GABA-B receptors in the spinal cord, dampening reflexes. Side effects include drowsiness, weakness and, if stopped suddenly, withdrawal symptoms and seizures.

10. Tizanidine
Tizanidine is another muscle relaxant that reduces muscle tone and spasms. Labels indicate use for spasticity; in neuropathic conditions it is off-label.FDA Access Data Dosing usually begins very low several times a day because of sedation and low blood pressure. Purpose is to ease cramping and improve comfort. Mechanism is α2-adrenergic agonism in the spinal cord, which reduces excitatory signals. Side effects include drowsiness, dizziness, low blood pressure and liver enzyme changes.

11. Topical lidocaine patches or creams
Lidocaine 5% patches are FDA-approved for post-herpetic neuralgia and used off-label for other focal neuropathic pains.FDA Access Data+1 The purpose is to numb a painful skin area without strong systemic effects. Mechanism is local sodium-channel blockade in peripheral nerve endings. Side effects are usually mild, such as skin irritation, but high doses over large areas should be avoided.

12. Topical capsaicin (high-strength patches or low-dose creams)
Capsaicin creams and high-dose patches (8%) are used for localized neuropathic pain, such as post-herpetic neuralgia.FDA Access Data+1 Purpose is to reduce pain in a small, well-defined area, like a very sensitive patch on the foot. Mechanism is desensitization of TRPV1 pain fibers after repeated exposure. Side effects include burning and redness at the application site.

13. Carbamazepine / oxcarbazepine (selected cases)
These older anti-seizure drugs are sometimes used for sharp, electric-shock-like neuropathic pains. FDA labels focus on seizures and trigeminal neuralgia.FDA Access Data+1 The purpose is to reduce paroxysmal shooting pains. Mechanism is sodium-channel blockade in hyper-excitable neurons. Side effects include dizziness, low sodium, liver and blood problems, so careful monitoring is needed.

14. Lamotrigine
Lamotrigine is another anti-seizure medicine used off-label for some neuropathic pain patterns and mood stabilization.FDA Access Data+1 The purpose is to stabilize nerve firing and sometimes help mood. Mechanism involves blockade of voltage-dependent sodium channels and reduced glutamate release. Side effects can include rash (rarely severe), dizziness and headache.

15. SSRIs (e.g., sertraline, citalopram) for mood
Selective serotonin reuptake inhibitors are mainly antidepressants, not primary pain drugs. However, treating depression and anxiety in chronic CMT can indirectly reduce pain impact and improve function.FDA Access Data+1 Purpose: support mental health and coping, which is essential in long-term disease. Mechanism: increase serotonin in brain circuits for mood. Side effects include nausea, sexual dysfunction and sleep changes.

16. Sleep medicines (used sparingly)
Short-term use of certain sleep aids may be considered when neuropathic pain severely disrupts sleep, always under close medical supervision.FDA Access Data Purpose is to break cycles of insomnia and fatigue. Mechanism depends on the drug (for example, GABA agonism for some hypnotics). Many have serious risks (dependence, falls, confusion), so non-drug sleep strategies are preferred first.

17. Botulinum toxin injections for painful deformities (selected cases)
In some complex foot deformities with focal spasm or over-active muscles, botulinum toxin injections may help.Charcot-Marie-Tooth Disease+1 The purpose is to relax specific muscles that worsen deformity or pain. Mechanism is blocking acetylcholine release at the neuromuscular junction. Side effects include temporary weakness and rare spread of toxin effects.

18. Short-term opioids for acute pain (e.g., after surgery)
Strong opioids may be used for a short time after major foot or spine surgery in CMT.Charcot-Marie-Tooth Disease+1 Purpose is to control intense acute pain so that people can mobilize and do rehab. Mechanism is μ-opioid receptor agonism in the brain and spinal cord. Risks include dependence, overdose, constipation, nausea and breathing suppression, so they must be time-limited and carefully supervised.

19. Vitamin B12 or folate replacement (if deficient)
If testing shows vitamin B12 or folate deficiency, replacement can help overall nerve health and prevent extra neuropathy on top of CMT.PMC+1 Purpose is to correct reversible contributors to nerve damage. Mechanism: these vitamins are essential for myelin and DNA synthesis in nerve cells. Excessive doses without deficiency usually do not add benefit and may cause side effects.

20. Treatment of other medical problems
Drugs that control diabetes, thyroid disease, autoimmune disease or other conditions that also damage nerves can indirectly help by removing extra stress from already fragile peripheral nerves.PMC Purpose is to avoid “double hits” to the nervous system. Mechanism is prolonging nerve survival by optimizing whole-body health.

---

Dietary Molecular Supplements

Evidence for supplements in CMTDIC is limited, and most data come from general neuropathy or mitochondrial disease studies. Always discuss supplements with a doctor, especially to avoid interactions.PMC+1

1. Omega-3 fatty acids (fish oil)
Omega-3 fats from fish oil or algae have anti-inflammatory and possible nerve-protective effects. They may modestly improve cardiovascular health and reduce low-grade inflammation that could worsen neuropathic pain. A typical general-health dose is often around 1 g/day of combined EPA/DHA, but doses vary. They work by changing cell-membrane lipids and lowering pro-inflammatory mediators. Side effects can include stomach upset and, in high doses, bleeding risk, especially with blood thinners.

2. Vitamin D
Vitamin D deficiency is common and may worsen muscle weakness and bone health. Replacing low vitamin D (for example 800–2000 IU/day, adjusted by blood levels) can support muscle function and reduce fracture risk from falls. The mechanism is improved calcium balance, bone strength and possible effects on muscle fiber function and immunity. Too much vitamin D can cause high calcium, kidney problems and nausea, so levels should be monitored.

3. Vitamin B12
Even mild B12 deficiency can worsen neuropathy symptoms. In deficient people, oral or injectable B12 can improve nerve conduction and reduce numbness or tingling. Doses may range from oral daily tablets to periodic injections, depending on cause of deficiency. Mechanism: B12 is crucial for myelin and DNA synthesis in nerves. Side effects are usually minimal, but masking of other deficiencies is a concern if not properly tested.

4. Alpha-lipoic acid
Alpha-lipoic acid is an antioxidant used in some countries for diabetic neuropathy. It may reduce oxidative stress in nerves and slightly ease pain or burning. Doses in studies often range around 600 mg/day, but long-term safety in CMT is not well studied. Mechanism is scavenging free radicals and improving mitochondrial function. Side effects include stomach upset, skin rash and possible low blood sugar in people on diabetes drugs.

5. Coenzyme Q10 (CoQ10)
CoQ10 supports mitochondrial energy production. In some mitochondrial or muscle disorders, it may improve fatigue. Typical doses are 100–300 mg/day with food, but evidence in CMT is limited. Mechanism: it transports electrons in the mitochondrial chain and stabilizes cell membranes. Side effects are usually mild (nausea, diarrhea), but interactions with blood thinners are possible.

6. L-carnitine
L-carnitine helps transport fatty acids into mitochondria for energy. It has been used in some neuromuscular conditions to help fatigue. Doses vary widely, often in the 1–3 g/day range in studies. Mechanism: improving energy metabolism in muscle and possibly nerves. Side effects can include stomach upset and a fishy body odour at high doses. Evidence in CMTDIC specifically is weak.

7. Magnesium
Magnesium is important for muscle relaxation and nerve function. Correcting low magnesium, for example with 200–400 mg/day as glycinate or citrate, may reduce muscle cramps and support general neuromuscular health. Mechanism is stabilizing cellular electrical activity and acting as a natural calcium blocker. High doses can cause diarrhea and, in people with kidney disease, dangerous magnesium accumulation.

8. Curcumin (turmeric extract)
Curcumin has anti-inflammatory and antioxidant actions and is studied in many chronic diseases. It may modestly reduce pain and inflammation in some people. Doses vary, often 500–1000 mg/day of standardized extract, preferably with piperine or a formulated high-absorption product. The mechanism is inhibition of NF-κB and other inflammatory pathways. Side effects include stomach upset and potential interaction with blood thinners.

9. L-serine (experimental)
L-serine is being studied in certain toxic neuropathies where abnormal fatty molecules (sphingolipids) damage nerves. In those contexts, high-dose L-serine may reduce harmful lipid production. Doses in trials are much higher than usual dietary intake and must be doctor-supervised. Mechanism: shifting how sphingolipids are synthesized. For CMTDIC, evidence is experimental only, and routine use is not currently recommended outside research.

10. Multivitamin and balanced micronutrient support
A simple, moderate-dose multivitamin can help cover small gaps in diet (for example, mild lack of B-vitamins, zinc or trace elements) that might slightly worsen fatigue or overall health. Doses follow label instructions. Mechanism is broad support of enzyme systems and cellular repair. Very high doses beyond recommended daily allowances are rarely helpful and can even be harmful, so “more” is not always “better”.

---

Regenerative / Immunity-Related and Stem-Cell-Linked Therapies

For CMTDIC, no FDA-approved regenerative or stem-cell drugs exist yet. Research is active, especially in other CMT types like CMT1A, and these approaches may guide future treatments.PMC+1

1. Gene-replacement or gene-editing therapies
Gene therapy tries to deliver a healthy copy of the faulty gene (for CMTDIC, often YARS1) or to edit the mutation directly using viral vectors like AAV. These methods are still at laboratory or very early clinical-trial stages. The purpose is to correct the root genetic cause. Mechanism: cells receive new genetic instructions so nerve cells can make normal proteins again. Risks include immune reactions and off-target effects, so research is careful and slow.

2. Small molecules that improve tRNA synthetase function
Because CMTDIC can be linked to YARS1, researchers are exploring small molecules that stabilize or modulate this enzyme. The aim is to correct the way nerve cells read genetic code for proteins. Mechanism: changing the folding or activity of tyrosyl-tRNA synthetase so that it behaves more normally. These are pre-clinical and not available as standard treatment.

3. Schwann cell or mesenchymal stem-cell therapies
Some studies in animals and early human trials for other CMT types look at transplanting supportive cells or using stem-cell-derived products to improve myelination and nerve repair.PMC+1 The purpose is to support remyelination and nerve regeneration. Mechanism: transplanted cells may create growth factors and myelin, or modulate immune responses. At present, these are experimental and not routine care.

4. Neurotrophic factor therapies
Neurotrophic factors (like BDNF, NGF or their mimics) are proteins that help nerves survive and grow. Trials in other neuropathies test drugs that boost these pathways. Purpose is to protect existing nerve fibers and promote regrowth. Mechanism is activating survival and growth signaling in neurons and Schwann cells. Results so far are mixed, and none is specifically approved for CMTDIC.

5. Immunomodulatory biologics (for overlapping autoimmune neuropathy)
If a person with CMTDIC also has an autoimmune neuropathy or inflammatory process, treatments like intravenous immunoglobulin (IVIG) or other biologics may be considered.PMC Purpose is to control immune-mediated damage that worsens neuropathy. Mechanism: IVIG and biologics change antibody and immune-cell activity. These drugs are powerful and used only when clear autoimmune features are present.

6. General immune and health support (vaccines, infection control)
While not “drugs” in the classic sense, staying up-to-date with vaccines (like influenza and pneumonia) and promptly treating infections helps prevent sudden worsening from illness and immobility.PMC+1 Purpose is to protect overall health so nerves face fewer extra stresses. Mechanism is giving the immune system targeted training and reducing systemic inflammation.

---

Surgeries

1. Tendon transfer surgery
When certain muscles are very weak and others still work, surgeons can move (transfer) a functioning tendon to take over the job of a weak one, especially around the ankle and toes.Charcot-Marie-Tooth Disease+1 This is done to correct foot drop and improve push-off. Mechanism is mechanical: the transferred tendon pulls the joint in a better direction during walking.

2. Foot osteotomy (bone-cutting surgery)
In severe pes cavus or other deformities, the surgeon may cut and realign foot bones to place the foot in a more normal shape.Charcot-Marie-Tooth Disease+1 This is done to spread weight more evenly, reduce pain and improve shoe wear. Mechanism is changing the architecture of the foot so that braces work better and walking is less painful.

3. Triple arthrodesis or ankle fusion
If joints are very stiff, painful and deformed, fusing some of them may give a more stable, plantigrade foot.Charcot-Marie-Tooth Disease+1 This is done mainly in advanced disease when other options fail. Mechanism: by permanently locking joints in a corrected position, pain and instability can be reduced, although some flexibility is lost.

4. Corrective toe surgery
Hammer toes and clawed toes are common in CMT. Small procedures can straighten toes, release tight tendons or remove painful corns.Charcot-Marie-Tooth Disease+1 The aim is to improve comfort in shoes and reduce ulcer risk. Mechanism is simple structural correction of toe position.

5. Spine surgery for scoliosis (in selected cases)
If scoliosis becomes severe or affects breathing, spinal fusion or other corrective procedures may be considered.PMC+1 Purpose is to prevent progression, protect lungs and reduce pain. Mechanism: rods and screws stabilize the spine in a straighter alignment.

---

Preventions

Because CMTDIC is genetic, we cannot prevent the basic mutation with lifestyle. But we can prevent or delay many complications:

1. Avoid nerve-toxic drugs (some chemotherapy agents, high-dose metronidazole, etc.) whenever alternatives exist, as advised by doctors.PMC

2. Control other diseases like diabetes or thyroid disorders that can cause extra neuropathy.PMC+1

3. Maintain a healthy weight to reduce load on weak ankles and hips.

4. Use proper footwear and orthoses early to slow deformity and prevent ulcers.Pod NMD+1

5. Do regular physiotherapy and stretching to reduce contractures and stiffness over time.physio-pedia.com+1

6. Protect feet and check skin daily, especially if sensation is reduced, to catch blisters and sores early.nhs.uk+1

7. Adapt the home environment to reduce fall risks (handrails, good lighting, no loose rugs).nhs.uk+1

8. Stay up-to-date with vaccines and treat infections quickly to avoid long inactive periods.PMC+1

9. Do not smoke and limit alcohol, because both can worsen nerve and muscle health.PMC+1

10. Seek genetic counselling before pregnancy to understand inheritance risks and options.Orpha+1

---

When to See Doctors

You should see a neurologist or neuromuscular specialist if you notice gradually increasing foot weakness, frequent ankle sprains, high arches, hammertoes or a family history of CMT-like problems. Early diagnosis allows earlier bracing and therapy.NCBI+2Orpha+2

People already diagnosed with CMTDIC should seek medical review urgently if:

• Pain suddenly worsens or changes in character (sharp, burning, electric).

• You develop new weakness in arms, face, or breathing problems.

• Walking becomes much harder or falls increase.

• You get a non-healing sore, ulcer or infection on the feet.

• There is severe back pain with bladder or bowel problems (possible spinal emergency).

Regular follow-up (often once or twice a year) with the multidisciplinary team is important to adjust braces, review therapy programs and update family planning or genetic information.PMC+1

---

What to Eat and What to Avoid

1. Eat a balanced, whole-food diet rich in vegetables, fruits, whole grains, legumes and lean protein to support overall nerve and muscle health.PMC+1

2. Include healthy fats such as olive oil, nuts, seeds and fatty fish (omega-3s) for anti-inflammatory support.PMC+1

3. Choose adequate protein (fish, chicken, eggs, dairy, tofu, pulses) to support muscle repair and strength.

4. Make sure you get enough calcium and vitamin D through diet (dairy, fortified foods, leafy greens) and, if needed, supplements, to protect bones.PMC+1

5. Limit highly processed foods high in sugar, refined flour, salt and trans fats, as they promote inflammation and weight gain.

6. Avoid heavy alcohol use, which can damage nerves further and increase falls.PMC+1

7. Drink enough water to help circulation, bowel function and medication tolerance.

8. Be cautious with “mega-dose” supplements not recommended by your doctor; more is not always better and can damage liver, kidneys or nerves.PMC+1

9. If you have diabetes or pre-diabetes, follow a low-glycaemic, controlled-carbohydrate plan to protect nerves from high blood sugar.PMC+1

10. Work with a dietitian if you struggle with weight, appetite, special diets or swallowing problems, to create a safe, enjoyable plan.

---

FAQs

1. Is autosomal dominant intermediate CMT type C curable?
No. At present there is no cure and no drug that reverses the underlying gene change.PMC+1 Treatment focuses on rehabilitation, orthoses, surgery and symptom-control drugs to improve quality of life and delay complications.

2. How fast does the disease progress?
Progression is usually slow and gradual over many years.NCBI+1 Many people remain able to walk, especially with braces and therapy, although some may eventually need canes or wheelchairs for distance.

3. What does “intermediate” mean in this disease name?
“Intermediate” refers to nerve conduction speeds that are between those seen in demyelinating CMT1 and axonal CMT2.NCBI+1 It describes the pattern on nerve conduction tests, not how severe the symptoms feel.

4. Is CMTDIC always caused by YARS1 mutations?
Most known families with this subtype have changes in YARS1, but classification is evolving and other genes may be involved as science advances.cmtausa.org+1 Genetic testing panels help confirm the exact gene in each person.

5. Can exercise make my nerves worse?
Heavy, high-impact or very intense exercise can over-stress weak muscles and joints. However, properly guided physiotherapy and low-impact exercise are protective, not harmful.physio-pedia.com+2MDPI+2

6. Can children with CMTDIC play sports?
Many can play adapted, low-impact sports like swimming, cycling or seated activities, especially when guided by therapists and using braces.physio-pedia.com+1 Contact sports and activities with high fall risk may need to be limited.

7. How is CMTDIC diagnosed?
Diagnosis usually combines family history, neurological exam, nerve conduction studies, EMG and genetic testing.NCBI+1 Sometimes MRI or nerve biopsy is used in complex cases.

8. Is pregnancy safe for someone with CMTDIC?
Most people with CMT can have safe pregnancies with careful monitoring.PMC+1 Symptoms may temporarily worsen because of weight gain and hormonal changes. Genetic counselling helps discuss the 50% inheritance risk.

9. Does CMTDIC affect life expectancy?
For most, life expectancy is near normal, but quality of life can be affected by pain, falls and disability.PMC+1 Serious complications like severe scoliosis or breathing problems are less common and can often be monitored.

10. Can diet alone treat CMTDIC?
No diet can reverse the gene change, but a balanced, anti-inflammatory diet and healthy weight can support muscles, bones and general health, reducing some complications and helping energy levels.PMC+1

11. Are there clinical trials for CMTDIC?
Trials exist mostly for other CMT types, but some include broader CMT groups or target shared mechanisms like myelination and axonal health.PMC+1 Clinical-trial registries and CMT organizations can help people search for opportunities.

12. Should family members be tested for the gene?
Genetic testing of family members is a personal decision.Orpha+1 Benefits include early monitoring and informed reproductive choices; drawbacks include anxiety and insurance or employment concerns in some settings. A genetic counsellor can guide this.

13. Why do my feet deform over time?
Because some foot muscles become weak and others stay relatively strong, unbalanced forces slowly reshape the foot, leading to high arches, clawed toes and ankle instability.Pod NMD+1 Braces, therapy and early surgery aim to rebalance these forces.

14. Is it safe to have surgery if I have CMTDIC?
Many people with CMT successfully have foot or spine surgery when needed.Charcot-Marie-Tooth Disease+1 An experienced anaesthetist and surgeon should plan carefully, especially around positioning, nerve protection, pain control and rehabilitation.

15. What is the most important thing I can do now?
The single most important step is to build a long-term partnership with a neuromuscular team and stay active within safe limits.PMC+1 Regular physiotherapy, appropriate braces, healthy lifestyle choices and emotional support together do more than any one pill we currently have.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 23, 2025.